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StlmEIlllry 
The primary response gene egr-1 encodes a sequence-specific transcription factor whose expres- 
sion is necessary for antigen receptor-stimulated activation of B lymphocytes. The molecular 
processes involved in linking egr-1 induction to antigen receptor signaling have not been defined. 
The present study demonstrates that expression of an activated form of p21 =~ results in egr.1 
induction similar to that previously shown after antigen receptor cross-linking.  In addition, both 
antigen receptor cross-linking and p21 =~ use the same element in the egr-1 promoter to exert 
their effects. Using dominant-negative mutants of p21 =' and raf-1, we demonstrate that induc- 
tion of egr-1 after antigen receptor cross-linking is mediated by activation of the p21=~/mitogen - 
activated protein kinase signaling pathway.  While regulation of the p21 =* pathway during B 
cell activation has been intensively studied, this report represents the first description of a biolog- 
ically relevant  event associated with its activation. 
.•tivation 
and differentiation of B  lymphocytes is ini- 
tiated by an interaction between a multivalent antigen 
and the antigen receptor (BCR) on the cell surface. As the 
activation signal enters the cytoplasm, a variety of biochem- 
ical changes can be detected. These changes include phos- 
photidylinositol hydrolysis with subsequent Ca  2+ mobiliza- 
tion and protein kinase C  (PKC)  activation, and increased 
tyrosine kinase activity (for review see reference 1). In addi- 
tion, the low molecular weight G protein p21 ~a~ is activated 
after antigen receptor cross-linking on B cells (2-4). These 
studies were prompted by an early report that found that 
p21 r~s  colocalized  with  the  antigen  receptor  after  cross- 
linking and aggregation (5). 
The p2V  ~s signaling pathway has been characterized  in a 
variety of cell types. As a G protein, p21TM is active only in 
the GTP-bound state (6).  Two mechanisms for regulating 
the activation state of p21 =~ have been described.  Guanine 
nucleotide exchange factors (GEFs) augment the exchange 
of GDP for GTP and are positive activators, while GTPase 
activating proteins (GAPs) result in inactivation of p21  ~  (6). 
Directly downstream of p21  =' in this signaling pathway is 
the activation of the serine/threonine kinase raf-1 (7). The 
mechanism by which p21  r~ activates raf-1 is not entirely un- 
derstood, but recent reports suggest that it results from recruit- 
ment of raf-1 to the cell membrane (8,  9). Activated  raf-1 
phosphorylates members of the MAPK/EtLK kinase (MEK) 
family of dual specificity kinases (10). After phosphorylation, 
MEKs activate the mitogen activated protein kinases (MAPKs) 
by threonine and tyrosine phosphorylation (11). MAPK has 
been directly linked to the control of transcription due to 
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phosphorylation of certain transcription factors,  including 
c-JUN (12) and a group of ETS family members collectively 
known as p62TCF (13). While the linearity of the p21r"/ 
raf-1/MEK/MAPK pathway has been confirmed in many 
receptor systems,  points of divergence have also been de- 
scribed (14). 
In B lymphocytes, activation of the p21 =~ pathway after 
BCR cross-linking has been extensively studied (1). The GEF 
vav is activated  (15, 16) and the GAP factors p120 (3,  17) 
and neurofibromin (18) inactivated after BCR cross-linking. 
In addition, recent studies (18a) have shown recruitment of 
the GEF SOS-1 to the BCR following receptor cross-linking. 
Activation offal-l, MEK, and MAPK by BCR cross-linking 
have all been demonstrated (2). As yet, however, no down- 
stream effectors of the p21~/MAPK pathway have been de- 
scribed in B lymphocytes. This is in contrast to T lympho- 
cytes, where induction of the Ib2 gene, an event critical for 
antigen receptor-initiated proliferation, appears to be medi- 
ated by activation of the p21="/MAPK pathway (19, 20). 
Among the earliest genetic events detected after BCR cross- 
linking is induction of the primary response gene egr-1 (1). 
Antisense studies have demonstrated that induction of egr-1 
is necessary for antigen receptor-mediated activation of both 
B and T lyrnphocytes (21, 22). This is presumably accom- 
plished by induction of a second wave of function-related genes 
whose regulation is controlled by the transcription factor en- 
coded by egr-1. 
Our recent results indicate that egr-1 induction after BCR 
cross-linking requires a serum response element (SRE) and 
adjacent ETS motifs in the egr-1 promoter (McMahon, S.B., 
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similar combination of SKE/ETS motifs mediates c-fis in- 
duction in fibroblasts  in response  to serum growth factors 
(for review see reference 13). The c-J~s SRE is occupied by 
a ternary complex composed of a homodimer of serum re- 
sponse factor (S1LF) and a single molecule ofp62TCF, which 
binds the adjacent ETS motif(D). Transcription of c-fis results 
from phosphorylation of p62TCF by MAPK (13). Because 
of the similarity in expression pattern and regulatory elements 
between c-fis and egr-1, this study was undertaken to deter- 
mine whether the p21~'/MAPK pathway was responsible 
for egr-1 induction in B cells. Using dominant-negative mu- 
tants of p21 ~  and tar-l, we demonstrate that in B lympho- 
cytes, induction of egr-1 depends on activation of the p2P S 
pathway. This study represents the first demonstration of any 
functional consequence  of p21TM activation after BCK cross- 
linking. 
Materiah  and Methods 
B Lymphocyte Isolation and Culture.  The spleens of 8- to 12-wk 
BALB/c  mice (The Jackson Laboratory,  Bar Harbor, ME) were re- 
moved aseptically  from animals  killed  by cervical  dislocation.  Spleens 
were minced and T lymphocytes removed  by treatment with anti- 
Thy-l.2 (HO13.4) antiserum and rabbit complement (Pel-Freeze 
Biologicals, Rogers, AZ). Red blood cells were removed by hypo- 
tonic lysis  and the remaining cells spun over a 75% Percoll  cushion. 
Cells were placed in culture for 72 h in B cell assay  media (RPMI- 
1640 with 10% FCS, 2 mM t-glutamine, nonessential  amino acids, 
100/~g/ml each of penicillin and streptomycin, and 5  x  10 -s M 
2-ME) with LPS (Salmonella Typhosa;  Sigma  Chemical  Co., St. Louis, 
MO) at 50 #g/ml. After 72 h of culture, B cell blasts were tran- 
siently transfected with vectors, as described below. 
Plasmid Construction.  The reporter plasmid pBL395 contains 
egr-1 promoter sequences from  -395 to  +65 linked to the gene 
encoding chloramphenicol acetyltransferase  (CAT). The plasmid 
containing point mutations in SRE #4 was generated by the PCR 
method  with Vent (Exo-) polymerase (New  England Biolabs, 
Beverly, MA). The expression vector pEJ encodes a constitutively 
active form of cHa-ras (25) and was provided by Dr. R. Muschel 
(University  of Pennsylvania,  Philadelphia,  PA). The expression  vector 
pASN17 encodes a dominant-negative form of p21 ~'' (26) and was 
provided by Dr. G. Cooper (Harvard University,  Cambridge, MA). 
The expression  vector  pmt-NArafencodes  a dominant-negative  form 
of raf-1 (27) and was provided by Dr. D. Schaap (The Netherlands 
Cancer Institute, Amsterdam, The Netherlands). Plasmid DNA 
was isolated  by the anion-exchange  method (QIAGEN). DNA from 
multiple preparations was used in these studies, and results were 
uniformly consistent. 
Transient Transfection ofB Lymphocytes.  B cell blasts were tran- 
siently transfected essentially as described (28, 28a). Briefly, cells 
were washed once in transfection buffer (25 mM Tris-C1 [pH 7.4], 
137 mM NaC1, 5 mM KCI, 0.6 mM Na2HPO4, 0.7 mM CaC12, 
0.5 mM MgClz) prewarmed to 37~  and suspended in a sterile 
solution containing DEAE-dextran (Pharmacia  Fine Chemicals, Pis- 
cataway, NJ) at 500/~g/ml  in STBS and the indicated amounts 
of phsmid DNA. Generally, 5 x  107 cells were transfected  in 5 ml 
of this solution for 30 min at 37~  Cells were then washed once 
with STBS and suspended  at 106/ml in B cell assay  media (without 
LPS). Stimuli were added 24 h after transfection for PMA (Sigma 
Chemical Co.) (10 ng/ml), or 40 h after transfection  for BCR cross- 
linking. BCR cross-linking was accomplished  by the addition of 
goat anti-/~ heavy chain (Jackson lmmunoResearch Laboratories, 
Inc., West Grove, PA) antibodies at 20/~g/ml. 
CATAssay.  To assay  transfected  B cell blasts for CAT activity, 
cells were collected  48 h after transfection by centrifugation. After 
lysis, CAT activity was assessed as described previously (28, 28a). 
Results were quantitated on a Phosphorlmager (Molecular Dy- 
namics, Sunnyvale,  CA). CAT activity is presented as either per- 
cent conversion or fold induction. Fold induction is defined  by the 
ratio of the percentage of chloramphenicol  converted to acetylated 
forms in stimulated versus unstimulated cells. 
Results 
Expression of a Constitutively Active Form of p21 `~' Activates 
the egr-1 Promoter in B Lymphocytes.  Previous  studies have 
demonstrated that promoter elements including an SRE and 
two adjacent ETS motifs mediate egr-1 induction in response 
to BCR cross-linking (McMahon, S.B., and J.G. Monroe, 
manuscript submitted for publication).  Because  of recent 
studies  demonstrating that activation of the p21~s/MAPK 
pathway is responsible for SRE-dependent expression of  c-fis 
in fibroblasts  (13), the participation of this pathway in in- 
duction ofegr-1 in B lymphocytes was evaluated. B cell blasts 
were transiently transfected with a combination of a con- 
struct (pBL395) containing the egr-1 promoter upstream of 
the CAT reporter gene and the p21  ~' expression vector pEJ 
(25). pBL395 contains egr-1 promoter sequences from - 395 
to + 65 which includes four SKEs, a cAMP response element, 
and a binding site for the EGR-1 protein, as well as potential 
binding sites for other transcription factors  (23).  The pEJ 
vector encodes a p21 ~' molecule, which is constitutively ac- 
tive due to a substitution at amino acid 12 (glycine "~ va- 
line), resulting in decreased GTP hydrolysis and accumula- 
tion of p21 r~ molecules in the active, GTP-bound form (25). 
As is evident in Fig.  1, cotransfection of pEJ resulted in a 
dose-dependent increase in transcription from the egr-1 pro- 
moter as assessed  by CAT activity. Cotransfection of the empty 
vector (pBR322) had no detectable effect on egr-1 promoter 
activity. 
The Promoter Element Mediating egr-1 Induction by Activated 
p21 "~ Colocalizes with the Element Mediating Induction by BCR 
Cross-linking.  While the results presented in Fig. 1 indicate 
that activated p2P' causes an increase  in the activity of a 
construct containing a large region of the egr-1 promoter, 
these data fail to  address  whether p21  ~'  and BCR cross- 
linking use the same c/s-regulatory  elements. Our previous 
studies demonstrated that induction of egr-1 after BCR cross- 
linking in B lymphocytes was dependent on the presence of 
an SRE at  -360  (SRE  #4)  (McMahon,  S.  B.,  and J.  G. 
Monroe, manuscript submitted for publication). To deter- 
mine whether expression  of activated p21 ~  mimics BCR 
cross-linking in this regard, an egr-1 promoter containing a 
mutated version of SRE #4 was tested for activity in the pres- 
ence  of activated p21 ''~. Like pBL395,  this CAT reporter 
construct contains egr-1 promoter sequences from  -395 to 
+ 65. However, four point mutations were introduced into 
the core of SILE #4. These mutations have previously been 
shown to inhibit SRF binding to the c-j~s SRE and conse- 
quently abolish transcription mediated by this element (29). 
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Cotransfection of an activated form of p21~ results in a dose- 
dependent increase in egr-1 promoter activity. LPS-induced B cell blasts 
were transiently  transfected with 20 #g of the egr-1 promoter/CAT vector 
pBL395 along with the indicated amounts of either pEJ (o~n circles) or 
the empty cassette pBR322 (solid squares), pEJ encodes a constitutively 
active form of cHa-ras (25). Cells were harvested 48 h after transfection 
and lysates assayed for CAT activity. The results are expressed as the per- 
centage of chloramphenicol converted to acetylated forms. 
The wild-type or mutated versions ofpBL395 were cotrans- 
fected into B cell blasts with the p21 r~ expression vector 
pEJ.  As  shown  in  Fig. 2,  expression  of activated  p21 r~s 
strongly induced CAT activity from the wild-type egr-1 pro- 
moter (3.94%  conversion). Mutation of SRE #4 resulted in 
a marked decrease  in CAT activity (0.15% conversion). These 
values reflect a decrease  from 131-fold  induction with the wild- 
type promoter to 5-fold with the mutant SRE promoter (rel- 
ative to levels obtained with the empty cassette pBR322), 
indicating that SKE #4 is necessary for the induction ofegr-1 
promoter activity by p21 r~S. 
Expression of a Dominant-negative Mutant of p21 ~  Inhibits 
BCR-mediated Induction of egr-I in B Lyrnphocytes.  The demon- 
stration that egr-1 promoter activity is induced by a constitu- 
tively active form of p21 r~S fails to directly address the role 
of the endogenous p21 ~ molecule in mediating egr-1 induc- 
tion during BCK-mediated activation of B lymphocytes. To 
determine whether activation  of p21 ~  plays a role in this 
process during normal BCR signaling, a construct encoding 
a dominant-negative  mutant of p21 ~  (pASN17) was trans- 
fected  into  B  lymphocytes (26). The  dominant-negative 
p2P* mutant contains a substitution  at position 17 (serine 
-" asparagine) (26). Position 17 is adjacent to the nucleotide 
binding pocket and,  by analogy to other G proteins  (26), 
may be critical for interacting with the ~, phosphate of GTP. 
ASN17 is consequently 40-fold less efficient at binding GTP 
in vitro (26) and presumably inhibits the function of normal 
p21 r~ molecules by sequestering  the cellular pool of GEF 
into inactive complexes (6). Cotransfection studies were per- 
formed with pASN17 (or the empty vector, pMSG) together 
with the egr-1 promoter construct pBL395. As demonstrated 
in Fig. 3 A, the induction of egr-1 promoter activity after 
BCR cross-linking is decreased by •75%  by cotransfection 
of  pASN17. Induction ofegr-1 was inhibited at two different 
ratios of the dominant-negative/reporter vectors (1:20 and 
1:2). Somewhat unexpectedly, induction of egr-1 promoter 
activity in response to treatment with the phorbol ester PMA 
Figure 2.  Activated  p21~ induces egr-1 through the same promoter ele- 
ment necessary for antigen receptor-mediared induction. Transient trans- 
fections  were carried out by use of  either of  two separate  egr-1 promoter/CAT 
constructs. (A) Sequence of the egr-1 promoter region surrounding SKE 
#4. The top line indicates the wild-type sequence included in pBL395. 
The lower line indicates the sequence of the mutated version ~BL395m), 
with vertical  lines indicating nucleotides that were altered. (/3) The reporter 
constructs  (5 #g of pBL395 in lanes I  and 3 or pBL395mut  in lanes 2 
and 4) described above were cotransfected with 7.5 #g of either the acti- 
vated p21  r~, expression vector pEJ (lanes 1 and 2) or the empty cassette 
pBR322 (lanes 3 and 4). Cells were harvested 48 h after transfection, as 
described in Materials and Methods, and results of the CAT assay are dis- 
played. Values presented represent percent conversion. 
was also inhibited  by the expression of ASN17 (Fig. 3 B). 
Like the inhibition of antigen receptor-mediated  induction, 
this effect was evident at two different ratios of the dominant- 
negative/reporter  vectors. Inhibition of PMA-mediated egr-1 
induction by ASN17 suggests that at least some of the effects 
of PMA in B cells occur upstream of p21 r~s activation. 
Expression  of a Dominant.negative  Mutant  of raf-1 Inhibits 
Antigen  Receptor-mediated Induction of egr-1.  Activation  of 
p21 ~ by growth-promoting agents in all cell types that have 
been examined results in activation of MAPK. As discussed 
above, a key intermediate in this cascade is the serine/threo- 
nine kinase raf-1 (10). To determine whether p21 ~s activa- 
tion  after  antigen receptor cross-linking  was  functioning 
through this pathway, a dominant-negative version of raf-1 
(NAraf) was used (27). NAtal contains  only the NH2-ter- 
minal regulatory region of tar-l, lacks the COOH-terminal 
kinase domain, and efficiently blocks raf-l-mediated events 
(27). When an expression vector (pmt-NAraf) encoding the 
dominant-negative raf-1 mutant was cotransfected into B cells 
along with pBL395, induction ofegr-1 promoter activity was 
substantially  decreased (Fig. 4).  As with the p21 r~ domi- 
nant-negative vector, this decrease was evident whether the 
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Figure  3.  Expression  of a dominant-negative form of p21~ inhibits 
egr-1 induction in B cells. LPS-induced  B cell blasts were cotransfected 
with 20 #g of the egr-1 promoter/CAT construct pBL395 and 1 ttg (1) 
or 10 #g (10) of the p21~ dominant-negative expression vector pASN- 
17 (or the empty cassette  pMSG ). Transfected  cells were stimulated with 
either goat anti-# antibodies at 20 ~g/ml (/1) or PMA at 10 rig/m1 (B), 
as described in Materials and Methods. Results of the CAT assay are ex- 
pressed as fold induction. 
cells were stimulated with anti-/~ (63% inhibition) or PMA 
(89%  inhibition),  suggesting that  raf-1  plays  a role in the 
induction of egr-1 by BCR cross-linking or PMA treatment. 
Discussion 
The results presented here demonstrate that activation of 
the p21 r~s pathway couples antigen receptor cross-linking to 
induction of egr-1 in B lymphocytes. Transfection of a con- 
stitutively active form of p21 ~  resulted in a dose-dependent 
increase  in egr-1  promoter  activity.  Previous studies  (Mc- 
Mahon, S. B., and J. G. Monroe, manuscript  submitted for 
publication) demonstrated that induction of egr-1 after an- 
tigen receptor cross-linking requires the presence of a specific 
SRE,  that  is, SRE #4.  In this study, we demonstrate  that 
SRE #4 is also necessary for egr-1 induction in response to 
activated p21 ~. Finally, using dominant-negative mutants of 
p21TM and tar-l, we demonstrate that induction of egr-1 pro- 
moter activity after BCR cross-linking  involves  activation 
of the p21raVraf-1/MAPK  pathway. By using transient trans- 
fection of primary B cells, we have been able to directly im- 
plicate this pathway in  activation  of the egr-1  promoter. 
In addition to stimulation ofB lymphocytes by antigen recep- 
tor cross-linking, we examined the effects of PMA treatment. 
PMA treatment directly activates PKC. As such, the finding 
that the dominant-negative p21  ~  mutant inhibited the PMA 
effect was somewhat unexpected and suggests that the effect 
of PMA on egr-1 transcription is mediated through the p21 "~ 
pathway. When these studies were initiated, PKC activation 
had not been shown to effect any of the early events in the 
p21  TM pathway. Recent reports have suggested a mechanism 
for the inhibition  seen in Fig. 3 by demonstrating  that  in 
addition to activating PKC, PMA can directly bind and acti- 
vate the GEF vav (30).  This potential effect of PMA on an 
early regulatory component in the p21 ~' pathway may ex- 
plain  the results obtained here, which show that inhibitory 
mutants of p21TM and raf-1 block induction of egr-1 by PMA. 
As already noted, in B lymphocytes, egr-1 induction after 
BCK cross-linking  or by expression of an activation form 
of p21TM (shown  here)  requires  a  specific  SRE  (SRE  #4). 
This is noteworthy since the egr-1 gene contains five SREs, 
each of which are capable of binding  SKF and regulating 
transcription  in various cell types. In myeloid cells,  for ex- 
ample,  a variety of stimuli,  including PMA, preferentially 
require SRE #5 for induction (31), while in PC12 cells, SREs 
#1 and #2 are necessary for nerve growth factor-induced ex- 
pression (32). Similar to the studies presented here, expres- 
sion of the v-tar oncogene in fibroblasts induces egr-1 pro- 
moter activity with a preference for SRE #4 (33). These results 
suggest a requirement  for SRE #4 by receptors and stimuli 
that  activate the p21TM signaling  pathway. 
A potential explanation for preferential utilization of SRE 
#4  by  stimuli  that  activate  the  p21 "s  pathway  may  be 
provided by recent studies. Induction of c-fis by growth factors 
in fibroblasts results from phosphorylation  of p62TCF by 
MAPK (13). Furthermore, p62TCF binds to a subset of ETS 
motifs that are adjacent to SREs (13). In the egr-1 promoter, 
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Figure 4.  Expression  of a dominant-negative 
form of raf-1 inhibits e&r-1  induction in B cells. 
LPS-indu&-'d B cell bhsts were cotransfected 
with 15/~g of the egr-1 promoter/CAT con- 
struct pBL395  and 30/tg of the raf-1 dominant- 
negative expression  vector  pmt-NAraf (or the 
empty cassette pint). Transfected cells were 
stimulated with either goat anti-/~ antibodies 
at 20 ttg/ml (A) or PMA at 10 rig/m1 (B), as 
described in Materials and Methods. Relative 
CAT activity  is expressed  as percent conversion. 
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high affinity p62TCF binding sites occur at only three loca- 
tions,  two of which are adjacent  to SRE #4 (13,  23).  We 
have recently shown that  the two p62TCF binding motifs 
adjacent to SRE #4 are necessary for egr-1 promoter activity 
in response to BCR cross-linking or PMA treatment  (Mc- 
Mahon, S. B., and J. G. Monroe, manuscript submitted for 
publication). Therefore, the presence of these motifs adjacent 
to SRE #4 is likely to mediate its preferential utilization in 
response to antigen receptor activation of the p21TM pathway 
in B lymphocytes by allowing efficient ternary complex for- 
mation by p62TCF  and SRF. 
Involvement  of the  p21 r~'  pathway  in  BCR-generated 
signal transduction  in B lymphocytes has been the subject 
of intensive study. Consequently, a significant amount of in- 
formation  is  available  regarding  the proteins  that  regulate 
p21 r~S in B  cells  (4,  5,  15-17).  In  addition,  several  studies 
have identified the kinases that are active in this pathway (1, 
2). However, to date, no functional consequence of p21  ~S ac- 
tivation in B cells has been demonstrated. In this report, we 
show that induction ofegr-1, a gene whose expression is neces- 
sary for lymphocyte activation,  is  mediated  by the  p21 r~s 
pathway after cross-linking  of the B cell antigen  receptor. 
These findings assign a crucial role to p21  TM in B cell acti- 
vation. 
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